Clinical Trials Browser

Phase 1/2 × Completed × Epirubicin × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03277924 2024-08-13

ImmunoSarc

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT00066443 2023-08-04

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1/2 Completed

93 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00719550 2013-12-05

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Phase 1/2 Completed

130 enrolled

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT00021047 2012-03-08

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Phase 1/2 Completed

CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00705315 2010-08-19

Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Phase 1/2 Completed

46 enrolled

Breast

Breast Neoplasms

NCT00097383 2006-07-19

Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

Breast

Breast Neoplasms

Clinical Trials

B-IMMUNE

ImmunoSarc

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer